glp-1-based therapy Redefining Obesity Management: Beyond GLP-1 Monotherapy 🩺 The therapeutic landscape for obesity and Type 2 Diabetes is evolving rapidly with the emergence of dual-hormone agonists. While semaglutide (GLP-1 RA) has demonstrated landmark GLP-1 Receptor Agonists as Treatments

GLP-1 receptor agonists like semaglutide and tirzepatide are large, complex molecules (over 4,000 Daltons) that cannot effectively penetrate the skin barrier

The prospect of funding lifelong drug regimens for large populations is financially daunting and raises concerns about long-term sustainability

Data were reviewed for two studies: Women with obesity, diabetes, cardiovascular disease and other cardiometabolic disorders have a higher risk of pregnancy complications including preeclampsia, gestational diabetes, stillbirth, C-section and other outcomes

It is a standard component of pregnancy-related nausea treatment and is used in chemotherapy-induced nausea protocols